ADCK2

Across TCGA pan-cancer cohorts, ADCK2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ADCK2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ADCK2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ADCK2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, CCRCC, and GBM are the cancer types where ADCK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.778	0.973	.005	38	view →
CCRCC	OS	Median	III,IV	0.238	0.735	.020	14	view →
GBM	DFS	Tertile	All	0.180	0.403	.020	8	view →
LSCC	DFS	Median	II,III,IV	0.892	0.218	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ADCK2–LUAD (DFS)

Open the LUAD breakdown →